secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001628280-23-008080
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology Q3 revenue $12.8M (-3.2% YoY), operating loss $2.5M, adj EBITDA -$1.6M
--------------------------------------------------------------------------------

- Revenue declined 3.2% to $12.8M from $13.2M a year ago, driven by macro-related customer cancellations.
- Operating loss of $2.5M vs income of $0.83M in prior year; adjusted EBITDA loss of $1.6M vs positive $1.5M.
- Record quarterly bookings; cash on hand $11.6M with no debt; net cash from ops $1.6M in Q3.
- R&D spend increased $1.0M (46.8%) to $3.2M, mainly for therapeutic target discovery platform.
- CEO expects improved results in fiscal 2024; YTD revenue up 12.6% to $40.8M but operating loss of $2.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828023008080/0001628280-23-008080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828023008080/csbr-20230315.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-008080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer